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Abstract: 
P2X4 receptor has become an interesting molecular target for treatment and PET imaging of 
neuroinflammation and associated brain diseases such as Alzheimer’s disease. This study reports 
the first design, synthesis, radiolabeling and biological evaluation of new candidate PET P2X4 
receptor radioligands using 5-BDBD, a specific P2X4 receptor antagonist, as a scaffold.  5-(3-
Hydroxyphenyl)-1-[11C]methyl-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (N-
[11C]Me-5-BDBD analog, [11C]9) and 5-(3-Bromophenyl)-1-[11C]methyl-1,3-dihydro-2H-
benzofuro[3,2-e][1,4]diazepin-2-one (N-[11C]Me-5-BDBD, [11C]8c) were prepared from their 
corresponding desmethylated precursors with [11C]CH3OTf through N-[11C]methylation and
isolated by HPLC combined with SPE in 30-50% decay corrected radiochemical yields with 
370-1110 GBq/µmol specific activity at EOB. 5-(3-[18F]Fluorophenyl)-1,3-dihydro-2H-
benzofuro[3,2-e][1,4]diazepin-2-one ([18F]F-5-BDBD, [18F]5a) and 5-(3-(2-
[18F]fluoroethoxy)phenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one ([18F]FE-5-
BDBD, [18F]11) were prepared from their corresponding nitro- and tosylated precursors by 
nucleophilic substitution with K[18F]F/Kryptofix 2.2.2 and isolated by HPLC-SPE in 5-25% 
decay corrected radiochemical yields with 111-740 GBq/µmol specific activity at EOB. The 
preliminary biological evaluation of radiolabeled 5-BDBD analogs indicated these new 
radioligands have similar biological activity with their parent compound 5-BDBD. 
Keywords: Radiolabeled 5-BDBD analogs; P2X4 receptor; Radiosynthesis; Radioligand 
depletion experiment; Competitive binding assay; Positron emission tomography (PET). 
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1. Introduction 
 
The purinergic P2X receptors are a family of cation-permeable ligand gated ion channels that 
open in response to the binding of extracellular adenosine 5’-triphosphate (ATP).1 This 
ionotropic receptor family contains seven subunits P2X1-7. P2X receptors are involved in 
various physiological processes and associated with a variety of diseases including cancer, 
cardiovascular and neurological diseases.2 P2X7 and P2X4 receptors are two predominant 
subtypes expressed on immune and neural cells. The over expression of P2X7 and P2X4 
receptors is linked to neuroinflammation, which is an essential step in the progression of brain 
diseases.3 Both P2X7 and P2X4 receptors have become a novel molecular target for treatment 
and PET (positron emission tomography) imaging of neuroinflammation and associated brain 
diseases such as Alzheimer’s disease.4 In our previous work, we have developed 
[11C]GSK14821605,6 as a new PET probe for imaging of P2X7 receptor as indicated in Figure 1. 
In this ongoing study, we first target P2X4 receptor and develop PET P2X4 receptor 
radioligands. Despite the therapeutic potential of P2X4 receptor antagonists, only a very limited 
number of inhibitors are known so far. Subsequently, the structure-activity relationship (SAR) 
information of P2X4 receptor antagonists is limited as well. However, potent and selective P2X4 
receptor antagonists are required as research tools for investigating the physiological functions of 
P2X4 receptor. 5-BDBD (5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-
one) is a specific P2X4 receptor antagonist with an IC50 of 500 nM in Chinese hamster ovary 
cells (CHO).7 Here we report the design, synthesis, radiolabeling and preliminary biological 
evaluation of a series of radiolabeled 5-BDBD analogs as new candidate P2X4 receptor 
radioligands as shown in Figure 2. 
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Figure 1. P2X7 receptor ligand GSK1482160 and radioligand [11C]GSK1482160. 
 
 
Figure 2. P2X4 receptor antagonist 5-BDBD and radiolabeled 5-BDBD analogs. 
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2. Results and discussion 
 
2.1. Chemistry 
 
5-BDBD can be directly radiolabeled with bromine-76 as [76Br]5-BDBD ([76Br]5c) using either 
chloro-precursor or tributylstannyl precursor.8,9 However, our cyclotron does not produce 
bromine-76, thus we focus on the synthesis of carbon-11 and fluorine-18 labeled 5-BDBD 
analogs. The novel P2X4 receptor radioligands proposed for development are based on direct N-
[11C]methylation at amide position of 5-BDBD and replacement of the bromo group of 5-BDBD 
with an O-[11C]methoxy, [18F]fluoro or [18F]fluoroethoxy group. Our initial design is to 
synthesize O-[11C]Me-5-BDBD ([11C]5f), N-[11C]Me-5-BDBD ([11C]8c), [18F]F-5-BDBD 
([18F]5a) and [18F]FE-5-BDBD ([18F]11) (Figure 2). 
 
5-(3-Substituted phenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one analogs 5a-5f   
were synthesized as outlined in Scheme 1. Starting from commercially available 2-
hydroxybenzonitrile, it underwent alkylation with 3-substituted phenacyl bromides 1a-1f in the 
presence of Na2CO3 in N,N-dimethylformamide (DMF) to obtain intermediate 2-(2-(3-
substituted phenyl)-2-oxoethoxy)benzonotriles 2a-2f, which were cyclized with sodium 
methoxide in MeOH to provide (3-aminobenzofuran-2-yl)-(3-substituted phenyl)methanones 3a-
3f in yields 82-98%.10 As shown in Scheme 1, compound 1d was achieved by α-bromination of 
3-iodoacetophenone with copper (II) bromide in EtOAc/CHCl3 in 67% yield.11,12 Acylation of 
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amines 3a-3f with bromoacetyl bromide in the presence of NaHCO3 in CHCl3 afforded 2-bromo-
N-(2-(3-substituted benzoyl)benzofuran-3-yl)acetamide 4a-4f in yields 75-89%. Treatment of 
4a-4f with ammonia in dioxane for cyclization to give 5a-5f in yields 58-92%.13 
 
 
Scheme 1. Synthesis of 5-BDBD analogs 5a-5f. 
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Scheme 2. Synthesis of 5-BDBD analogs 6, 8c, 8f, 10 and 11. 
 
As depicted in Scheme 2, desmethylation14,15 of 5f with BBr3 in CH2Cl2 afforded the precursor 5-
(3-hydroxyphenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (6) in 81% yield. 
Methylation of 5c, 5f with CH3I in the presence of NaH in DMF gave N-
methylbenzodiazepinone 8c, 8f in 65% and 90% yield, respectively. O-alkylation of 6 with 1,2-
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bis(tosyloxy)ethane or 2-fluoroethyl tosylate in the presence of NaH in DMF,16 gave the 
tosylated precursor 2-(3-(2-oxo-2,3-dihydro-1H-benzofuro[3,2-e][1,4]diazepin-5-
yl)phenoxy)ethyl 4-methylbenzenesulfonate (10) and reference standard 5-(3-(2-
fluoroethoxy)phenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (11) in 65% and 43% 
yield, respectively. 
 
 
Scheme 3. Radiosynthesis of N-[11C]Me-5-BDBD analog ([11C]9). 
 
The precursor 6 underwent [11C]methylation17,18 using a reactive [11C]methylating agent 
[11C]methyl triflate ([11C]CH3OTf)19,20 in acetonitrile at 80 οC under basic condition (NaH) to 
obtain an unexpected radiolabeled product 5-(3-hydroxyphenyl)-1-[11C]methyl-1,3-dihydro-2H-
benzofuro[3,2-e][1,4]diazepin-2-one (N-[11C]Me-5-BDBD analog, [11C]9). The expected 
radiolabeled product O-[11C]Me-5-BDBD ([11C]5f) was not formed. For compound 6, its amide 
N-H is more reactive than the phenol O-H. [11C]Methylation of the precursor 6 is outlined in 
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Scheme 3. The product was isolated by semi-preparative reverse-phase (RP) high performance 
liquid chromatography (HPLC) with a C-18 column, and then concentrated by solid-phase 
extraction (SPE)21,22 with a disposable C-18 Light Sep-Pak cartridge to produce the 
corresponding pure radiolabeled compound [11C]9 in 30-50% radiochemical yield, decay 
corrected to end of bombardment (EOB), based on [11C]CO2. [11C]CH3OTf is more reactive than 
commonly used [11C]methyl iodide ([11C]CH3I), and we use [11C]CH3OTf instead of [11C]CH3I 
as the radiolabeled precursor to improve the radiochemical yield.17,18 Acetonitrile (CH3CN) was 
found to be an appropriate reaction solvent for [11C]CH3OTf, and N,N-dimethylformamide 
(DMF) was found to be an inappropriate reaction solvent for [11C]CH3OTf since it reacted with 
and consumed a large portion of the radiolabel, especially under basic condition. 
[11C]CH3OTf/CH3CN for [11C]methylation would improve the radiochemical yield. 
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Scheme 4. The protecting reaction of 5-BDBD analog 6 with (Boc)2O. 
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As indicated in Scheme 4, in order to synthesize O-[11C]Me-5-BDBD, we attempted to protect 
the amide N-H of 6 with tert-butyloxycarbonyl (Boc) protecting group using 4-
dimethylaminopyridine (DMAP) as a catalyst,5,23 but we only obtained a phenol O-H protected 
product 7 in 44% yield. The bulky Boc-group would react with the phenol O-H of 6, instead of 
the amide N-H, and the steric effect was involved. 
 
 
Scheme 5. Synthesis of N-Me-5-BDBD analog (9). 
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Thus, we have no way to synthesize O-[11C]Me-5-BDBD. Then, we have to synthesize the 
reference standard 5-(3-hydroxyphenyl)-1-methyl-1,3-dihydro-2H-benzofuro[3,2-
e][1,4]diazepin-2-one (9) for N-[11C]Me-5-BDBD analog. As shown in Scheme 5, the direct 
methylation of 6 with CH3I in DMF provided a mixture containing 9, 5f, and 8f. The reaction 
was monitored by thin layer chromatography (TLC). From TLC, only very little 9 was observed. 
In addition, it was difficult to purify the methylation mixture. Therefore, we conducted O-
desmethylation14,15 of 8f with BBr3 in dichloromethane to afford 9 in 72% yield. CH3I/DMF for 
methylation would improve the chemical yield. 
 
The synthesis of 5-(3-bromophenyl)-1-[11C]methyl-1,3-dihydro-2H-benzofuro[3,2-
e][1,4]diazepin-2-one (N-[11C]Me-5-BDBD, [11C]8c) is depicted in Scheme 6. 5-BDBD was 
labeled with [11C]CH3OTf through N-[11C]Methylation24 under basic condition (NaH) and 
isolated by HPLC-SPE method to give the target tracer N-[11C]Me-5-BDBD in 30-50% decay 
corrected radiochemical yield. 
 
 
Scheme 6. Radiosynthesis of N-[11C]Me-5-BDBD ([11C]8c).  
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The 11C-radiosynthesis was performed in a home-built automated multipurpose [11C]-
radiosynthesis module.25,26 It included three stages: 1) labeling reaction; 2) purification; and 3) 
formulation. We used a vial-method for reaction; semi-preparative HPLC for purification; and 
Light Sep-Pak trap/release for formulation. Overall, it took ~40 min for synthesis, purification 
and dose formulation. Our [11C]-radiosynthesis module is designed to allow in-process 
measurement of [11C]-tracer specific activity (SA, GBq/µmol at EOB) using a radiation detector 
at the outlet of the HPLC-portion of the system. For the reported syntheses, product SA was in a 
range of 370-1110 GBq/µmol at EOB. The major factors including [11C]-target and [11C]-
radiosynthesis unit that affect the EOB SA significantly to lead to such a wide range from 370 to 
1110 GBq/µmol have been discussed in our previous works.18 The general methods to increase 
SA have been described as well, and the SA of our [11C]-tracers is significantly improved.18 The 
‘wide range’ of SA we reported is for the same [11C]-tracer produced in different days, because 
very different [11C]-target and [11C]-radiosynthesis unit situations would make SA in a wide 
range. For a [11C]-tracer produced in the same day, the SA of the same tracer in different 
production runs will be in a small range, because [11C]-target and [11C]-radiosynthesis unit would 
not be much different in the same day. Likewise, the methods to minimize such wide range of 
SA from practice perspective have been provided in our previous works.18 At the end of 
synthesis (EOS), the SA of [11C]-tracer was actually determined again by analytical HPLC,27 
calculated, decay corrected to EOB, and based on [11C]CO2, which was in agreement with the 
‘on line’ determined value. In each our [11C]-tracer production, if semi-preparative HPLC was 
used for purification, then the SA of [11C]-tracer was assessed by both semi-preparative HPLC 
(during synthesis) and analytical HPLC (EOS).  
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Scheme 7. Radiosynthesis of [18F]F-5-BDBD ([18F]5a) and [18F]FE-5-BDBD ([18F]11). 
 
As shown in Scheme 7, the nitro-precursor 5e was labeled with K[18F]F/Kryptofix 2.2.2 through 
nucleophilic substitution28 and isolated by the HPLC-SPE method to produce the corresponding 
radiolabeled product 5-(3-[18F]fluorophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-
one ([18F]F-5-BDBD, [18F]5a) in 5-15% decay corrected radiochemical yield from K[18F]F at 
EOB. Likewise, the tosylated precursor 10 was labeled with K[18F]F/Kryptofix 2.2.229 and 
isolated by HPLC-SPE to produce the corresponding radiolabeled product 5-(3-(2-
[18F]fluoroethoxy)phenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one ([18F]FE-5-
BDBD, [18F]11) in 15-25% decay corrected radiochemical yield. Using dimethyl sulfoxide 
(DMSO) as the reaction solvent and running radiolabelling reaction at 140 οC would increase the 
radiochemical yield.30 The effect of the reaction solvent and temperature on the radiochemical 
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yield has been studied in our previous work by direct comparison of DMSO/140 οC with 
CH3CN/120 οC.29  
 
The 18F-radiosynthesis was performed in an automated multipurpose [18F]-radiosynthesis module 
of our own design.16 The radiosynthesis process included labeling reaction, purification and 
formulation. The overall synthesis, purification and formulation time was ~70 min from EOB. 
The SA of [18F]-tracer can be assessed by both semi-preparative HPLC (during synthesis) and 
analytical HPLC (EOS).27 18F-product SA was in a range of 111-740 GBq/µmol at EOB. 
 
Chemical purity and radiochemical purity were determined by analytical HPLC.27 The chemical 
purity of the precursors (6, 5c, 5e, and 10) and reference standards (9, 8c, 5a, and 11) was >90%. 
The radiochemical purity of the target tracers ([11C]9, [11C]8c, [18F]5a, and [18F]11) was >99% 
determined by radio-HPLC through γ-ray (PIN diode) flow detector, and the chemical purity of 
the target tracers was >90% determined by reversed-phase HPLC through UV flow detector.    
      
2.2. In vitro binding studies 
 
The preliminary biological evaluation of the carbon-11 radioligands [11C]9 and [11C]8c was 
performed by a radioligand depletion experiment.6,31 In this experiment, a wide range of protein 
was used for the optimization of the assay conditions. For the law of mass action to be valid, the 
protein and radioligand concentration need to be at levels where no more than 10% of the total 
radioligand added is bound to the protein. Otherwise the radioligand is considered depleted and 
specialized formulas for radioligand depletion must be used for analysis of the data in saturation 
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or competitive binding assays. An optimized binding assay uses protein levels where the 
radioligand is depleted no more than 10%, and where sufficient signal to background binding 
levels, at least 5 fold total binding/non-specific binding ratio, are obtained. To achieve both of 
these ends, a wide range of membrane protein concentrations was tested to get the optimal level 
for the assay. The results indicated low affinity of [11C]9 and [11C]8c to P2X4 receptor. We 
suspected the radioligands might be too sticky. Then the method was further optimized by 
improving the solubility of the tracers [11C]9 and [11C]8c, and the results remained same. Thus 
the competitive binding assay of ligands 5-BDBD (5c), N-Me-5-BDBD (8c), N-Me-5-BDBD 
analog (9), F-5-BDBD (5a) and FE-5-BDBD (11) was conducted following the literature 
method31,32 with modifications using [35S]ATPγS as the radioligand, ATP as a positive control, 
and buffer as a negative control, respectively. The assays were incubated at 4 °C for 2 h. The 
results are shown in Figure 3, which showed new ligands we synthesized have similar biological 
activity in comparison with the parent compound 5-BDBD, because their binding curves are 
similar. These results suggest more potent PET P2X4 receptor radioligands remain to be 
discovered and developed. 
 
 
Figure 3. The results of the ligand competitive binding assay of 5-BDBD analogs. 
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3. Materials and methods 
 
3.1. General 
 
All commercial reagents and solvents were purchased from Sigma-Aldrich and Fisher Scientific, 
and used without further purification. [11C]CH3OTf was prepared according to a literature 
procedure.20 Melting points were determined on a MEL-TEMP II capillary tube apparatus and 
were uncorrected. 1H and 13C NMR spectra were recorded on a Bruker Avance II 500 MHz 
NMR Fourier transform spectrometer at 500 and 125 MHz, respectively. Chemical shifts (δ) are 
reported in parts per million (ppm) relative to an internal standard tetramethylsilane (TMS, δ 0.0) 
(1H NMR) and to the solvent signal (13C NMR), and coupling constants (J) are reported in hertz 
(Hz). Liquid chromatography-mass spectra (LC-MS) analysis was performed on an Agilent 
system, consisting of an 1100 series HPLC connected to a diode array detector and a 1946D 
mass spectrometer configured for positive-ion/negative-ion electrospray ionization. The high 
resolution mass spectra (HRMS) were obtained using a Waters/Micromass LCT Classic 
spectrometer. Chromatographic solvent proportions are indicated as volume: volume ratio. TLC 
was run using Analtech silica gel GF uniplates (5 × 10 cm2).  Plates were visualized under UV 
light. Preparative TLC was run using Analtech silica gel UV254 plates (20 × 20 cm2). Normal 
phase flash column chromatography was carried out on EM Science silica gel 60 (230-400 mesh) 
with a forced flow of the indicated solvent system in the proportions described below. All 
moisture- and air-sensitive reactions were performed under a positive pressure of nitrogen 
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maintained by a direct line from a nitrogen source. C18 Sep-Pak Light and Plus cartridges were 
obtained from Waters Corporation (Milford, MA). Sterile Millex-FG 0.2 µm filter units were 
obtained from Millipore Corporation (Bedford, MA). 
 
3.2. 2-Bromo-1-(3-iodophenyl)ethanone (1d) 
  
To a stirred solution of 3-iodoacetophenone (5.0 g, 20.3 mmol) in EtOAc/CHCl3 (100 mL/100 
mL) was added CuBr2 (9.1 g, 40.6 mmol). After the reaction mixture was heated under reflux for 
3.5 h, it was cooled and filtered through Celite. The solvent was evaporated in vacuo to afford 1d 
as a white solid (4.4 g, 67%), which was used for next step without further purification. 1H NMR 
(DMSO-d6): δ 8.30 (t, J = 2.0 Hz, 1H), 8.04 (dt, J = 1.0, 8.0 Hz, 1H), 8.00 (dt, J = 1.0, 8.0 Hz, 
1H), 7.37 (t, J = 8.0 Hz, 1H), 4.96 (s, 2H). 
 
3.3. General procedure for preparation of compound 3   
 
(3-Aminobenzofuran-2-yl)-(3-fluorophenyl)methanone (3a). A mixture of 2-hydroxybenzonitrile 
(1.0 g, 8.4 mmol), 2-bromo-1-(3-fluorophenyl)ethanone (1a, 2.0 g, 9.2 mmol) and Na2CO3 
(1.33g, 12.6 mmol) in anhydrous DMF (15 mL) was stirred at room temperature (RT) overnight. 
The reaction mixture was poured into water. The precipitate was collected by filtration and 
washed with water. The solid was dissolved in EtOAc, washed with brine, dried over anhydrous 
MgSO4, and filtered. After the solvent was evaporated in vacuo, MeOH (25 mL) was added to 
the intermediate solid, followed by addition of sodium methoxide (463 mg, 8.6 mmol). The 
reaction mixture was stirred and heated under reflux for 30 min. The mixture was cooled and 
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pour into ice-water. The precipitate was collected by filtration and washed with water. The solid 
was dried in vacuo to afford 3a as a yellow solid (2.0 g, 91%); mp 126-128 οC. 1H NMR 
(DMSO-d6): δ 8.08 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 7.5 Hz, 1H), 7.86-7.84 (m, 1H), 7.66-7.57 
(m, 5H), 7.48-7.45 (m, 1H), 7.34-7.30 (m, 1H). 
(3-Aminobenzofuran-2-yl)-(3-chlorophenyl)methanone (3b). Compound 3b was prepared with 
similar procedure as compound 3a from 1b. Yield: 82%, yellow solid; mp 122-124 οC. 1H NMR 
(DMSO-d6): δ 8.09-8.06 (m, 3H), 7.69-7.67 (m, 1H), 7.62-7.56 (m, 5H), 7.33-7.30 (m, 1H). 
(3-Aminobenzofuran-2-yl)-(3-bromophenyl)methanone (3c). Compound 3c was prepared with 
similar procedure as compound 3a from 1c. Yield: 87%, yellow solid; mp 102-104 οC. 1H NMR 
(DMSO-d6): δ 8.19 (t, J = 2.0 Hz, 1H), 8.13 (dt, J = 1.0, 8.0 Hz, 1H), 8.08 (d, J = 8.0 Hz, 1H), 
7.82-7.80 (m, 1H), 7.61-7.53 (m, 5H), 7.33-7.30 (m, 1H). 
(3-Aminobenzofuran-2-yl)-(3-iodophenyl)methanone (3d). Compound 3d was prepared with 
similar procedure as compound 3a from 1d. Yield: 88%, yellow solid; mp 138-140 οC. 1H NMR 
(DMSO-d6): δ 8.35 (t, J = 1.5 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.97-
7.96 (m, 1H), 7.60-7.54 (m, 4H), 7.39 (t, J = 8.0 Hz, 1H), 7.33-7.30 (m, 1H). 
(3-Aminobenzofuran-2-yl)-(3-nitrophenyl)methanone (3e). Compound 3e was prepared with 
similar procedure as compound 3a from 1e. Yield: 84%, yellow solid; mp 166-168 οC. 1H NMR 
(DMSO-d6): δ 8.85 (t, J = 2.0 Hz, 1H), 8.56 (d, J = 7.5 Hz, 1H), 8.46-8.44 (m, 1H), 8.11 (d, J = 
8.0 Hz, 1H), 7.88 (t, J = 8.0 Hz, 1H), 7.72 (br s, 2H), 7.63-7.60 (m, 1H), 7.56 (d, J = 8.0 Hz, 1H), 
7.35-7.32 (m, 1H). 
(3-Aminobenzofuran-2-yl)-(3-methoxyphenyl)methanone (3f). Compound 3f was prepared with 
similar procedure as compound 3a from 1f. Yield: 98%, yellow solid; mp 126-128 οC. 1H NMR 
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(DMSO-d6): δ 8.07 (d, J = 7.5 Hz, 1H), 7.73 (d, J = 7.5 Hz, 1H), 7.61 (br s, 1H), 7.58-7.48 (m, 
5H), 7.33-7.30 (m, 1H), 7.18 (dd, J = 2.0, 8.0 Hz, 1H). 
 
3.4. General procedure for preparation of compound 4  
 
2-Bromo-N-(2-(3-fluorobenzoyl)benzofuran-3-yl)acetamide (4a). To a stirred mixture of 
compound 3a (1.4 g, 5.3 mmol) and NaHCO3 (1.8 g, 51.3 mmol) in CHCl3 (25 mL) was added 
bromoacetyl bromide (0.6 mL, 6.9 mmol) dropwise at 0 οC. The reaction mixture was stirred at 0 
οC for 1.5 h. After the solvent was evaporated in vacuo, EtOAc was added to dissolve the 
residue. The organic solution was washed with saturated aqueous NaHCO3 and brine, dried over 
anhydrous Na2SO4, and filtered. The solvent was evaporated in vacuo. The crude product was 
washed with hexanes and Et2O to afford 4a as a yellow solid (1.8 g, 89%); mp 106-108 οC. 1H 
NMR (DMSO-d6): δ 10.90 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.88-7.86 (m, 1H), 7.79-7.75 (m, 
2H), 7.68-7.61 (m, 2H), 7.57-7.54 (m, 1H), 7.43-7.40 (m, 1H), 4.23 (s, 2H).  
2-Bromo-N-(2-(3-chlorobenzoyl)benzofuran-3-yl)acetamide (4b). Compound 4b was prepared 
with similar procedure as compound 4a from 3b. Yield: 75%, pale yellow solid; mp 112-114 οC. 
1H NMR (DMSO-d6): δ 10.90 (s, 1H), 7.98-7.95 (m, 3H), 7.77-7.74 (m, 2H), 7.64-7.61 (m, 2H), 
7.43-7.40 (m, 1H), 4.21 (s, 2H). 
2-Bromo-N-(2-(3-bromobenzoyl)benzofuran-3-yl)acetamide (4c). Compound 4c was prepared 
with similar procedure as compound 4a from 3c. Yield: 78%, yellow solid; mp 118-120 οC. 1H 
NMR (DMSO-d6): δ 10.89 (s, 1H), 8.08 (t, J = 2.0 Hz, 1H), 8.00 (dt, J = 1.0, 7.5 Hz, 1H), 7.97 
(d, J = 8.0 Hz, 1H), 7.90-7.88 (m, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.64-7.60 (m, 1H), 7.56 (t, J = 
8.0 Hz, 1H), 7.43-7.40 (m, 1H), 4.21 (s, 2H). 
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2-Bromo-N-(2-(3-iodobenzoyl)benzofuran-3-yl)acetamide (4d). Compound 4d was prepared with 
similar procedure as compound 4a from 3d. Yield: 88%, yellow solid; mp 140-142 οC. 1H NMR 
(DMSO-d6): δ 10.88 (s, 1H), 8.23 (t, J = 1.5 Hz, 1H), 8.06-8.04 (m, 1H), 8.01 (dt, J = 1.5, 7.5 
Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.64-7.60 (m, 1H), 7.43-7.38 (m, 
2H), 4.21 (s, 2H). 
2-Bromo-N-(2-(3-nitrobenzoyl)benzofuran-3-yl)acetamide (4e). Compound 4e was prepared with 
similar procedure as compound 4a from 3e. Yield: 87%, yellow solid; mp 150-152 οC. 1H NMR 
(DMSO-d6): δ 10.96 (s, 1H), 8.66 (t, J = 2.0 Hz, 1H), 8.52-8.50 (m, 1H), 8.41 (dt, J = 1.0, 8.0 
Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.89 (t, J = 8.0 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.66-7.63 
(m, 1H), 7.46-7.42 (m, 1H), 4.16 (s, 2H). 
2-Bromo-N-(2-(3-methoxybenzoyl)benzofuran-3-yl)acetamide (4f). Compound 4f was prepared 
with similar procedure as compound 4a from 3f. Yield: 87%, yellow solid; mp 122-124 οC. 1H 
NMR (DMSO-d6): δ 10.88 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 7.5 Hz, 1H), 7.64-7.60 
(m, 2H), 7.54-7.51 (m, 2H), 7.41 (t, J = 7.5 Hz, 1H), 7.28 (dd, J = 2.5, 8.5 Hz, 1H), 4.24 (s, 2H), 
3.85 (s, 3H). 
 
3.5. General procedure for preparation of compound 5 
 
5-(3-Fluorophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (F-5-BDBD, 5a). To a 
stirred compound 4a (1.0 g, 2.7 mmol) in dioxane (5 mL) was added ammonia (0.5 M solution in 
dioxane, 60 mL, 30.0 mmol). After the reaction mixture was stirred at RT for 2 days, EtOAc was 
added. The mixture was washed with water, brine, dried over anhydrous Na2SO4 and filtered. 
The solvent was evaporated in vacuo. The crude product was washed with MeOH to afford 5a as 
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a pale yellow solid (724 mg, 92%); mp 256-258 οC. 1H NMR (DMSO-d6): δ 11.60 (s, 1H), 8.00 
(d, J = 7.5 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.61-7.53 (m, 4H), 7.44-7.39 (m, 2H), 4.46 (s, 2H). 
13C NMR (DMSO-d6): δ 165.7, 162.9, 161.0 (d, J = 122 Hz), 153.6, 138.3, 130.4, 129.0, 128.6, 
125.2, 123.5, 120.8, 120.7, 117.5, 115.4, 112.4, 59.2. HRMS (ESI, m/z): Calcd for C17H12FN2O2 
([M+H]+) 295.0883, found: 295.0883. 
5-(3-Chlorophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (5b). Compound 5b 
was prepared with similar procedure as compound 5a from 4b. Yield: 62%, pale yellow solid; 
mp 263-264 οC. 1H NMR (DMSO-d6): δ 11.59 (s, 1H), 8.00 (d, J = 7.5 Hz, 1H), 7.77 (t, J = 2.0 
Hz, 1H), 7.72-7.70 (m, 2H), 7.63-7.61 (m, 1H), 7.60-7.56 (m, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.44-
7.41 (m, 1H), 4.46 (s, 2H). 13C NMR (DMSO-d6): δ 165.7, 160.0, 153.6, 138.2, 138.0, 133.2, 
130.4, 130.3, 129.0, 128.6, 128.4, 127.7, 123.5, 120.8, 120.7, 112.4, 59.2. HRMS (ESI, m/z): 
Calcd for C17H12ClN2O2 ([M+H]+) 311.0587, found: 311.0573. 
5-(3-Bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (5-BDBD, 5c). 
Compound 5c was prepared with similar procedure as compound 5a from 4c. Yield: 84%, pale 
yellow solid; mp 244-246 οC. 1H NMR (DMSO-d6): δ 11.59 (s, 1H), 8.00 (d, J = 7.5 Hz, 1H), 
7.91 (s, 1H), 7.76-7.73 (m, 2H), 7.70 (d, J = 8.0 Hz, 1H), 7.59-7.56 (m, 1H), 7.47 (t, J = 8.0 Hz, 
1H), 7.43 (t, J = 7.5 Hz, 1H), 4.46 (s, 2H). 
5-(3-Iodophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (5d). Compound 5d was 
prepared with similar procedure as compound 5a from 4d. Yield: 58%, pale yellow solid; mp 
245-246 οC. 1H NMR (DMSO-d6): δ 11.58 (s, 1H), 8.08 (t, J = 1.5 Hz, 1H), 8.00 (d, J = 8.0 Hz, 
1H), 7.91 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.59-7.56 (m, 
1H), 7.43 (t, J = 7.5 Hz, 1H), 7.30 (t, J = 8.0 Hz, 1H), 4.45 (s, 2H). 13C NMR (DMSO-d6): δ 
165.7, 159.9, 153.6, 139.1, 138.2, 138.0, 137.1, 130.5, 129.0, 128.6, 128.4, 123.5, 120.8, 120.7, 
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112.4, 94.6, 59.2. HRMS (ESI, m/z): Calcd for C17H12IN2O2 ([M+H]+) 402.9944, found: 
402.9930. 
5-(3-Nitrophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (5e). Compound 5e was 
prepared with similar procedure as compound 5a from 4e. Yield: 84%, pale yellow solid; mp 273 
οC (dec.). 1H NMR (DMSO-d6): δ 11.68 (s, 1H), 8.57 (t, J = 2.0 Hz, 1H), 8.41-8.39 (m, 1H), 
8.22 (dt, J = 1.0, 8.0 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.81 (t, J = 8.0 Hz, 1H), 7.70 (J = 8.5 Hz, 
1H), 7.62-7.58 (m, 1H), 7.46-7.43 (m, 1H), 4.52 (s, 2H). 
5-(3-Methoxyphenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (O-Me-5-BDBD, 5f). 
Compound 5f was prepared with similar procedure as compound 5a from 4f. Yield: 75%, off 
white solid; mp 224-225 οC. 1H NMR (DMSO-d6): δ 11.53 (s, 1H), 7.99 (d, J = 7.5 Hz, 1H), 7.69 
(d, J = 8.5 Hz, 1H), 7.59-7.55 (m, 1H), 7.44-7.28 (m, 2H), 7.30-7.28 (m, 2H), 7.13-7.11 (m, 1H), 
4.44 (s, 2H), 3.80 (s, 3H). 13C NMR (DMSO-d6): δ 165.9, 161.0, 159.1, 153.5, 138.8, 137.4, 
129.4, 128.6, 128.4, 123.4, 121.4, 120.8, 120.8, 116.4, 113.8, 112.3, 59.1, 55.2. HRMS (ESI, 
m/z): Calcd for C18H15N2O3 ([M+H]+) 307.1083, found: 307.1077. 
 
3.6. 5-(3-Hydroxyphenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (6) 
 
To a stirred suspension of compound 5f (1.1 g, 3.4 mmol) in anhydrous CH2Cl2 (30 mL) was 
added BBr3 (1.0 M solution in CH2Cl2, 30 mL, 30.0 mmol) dropwise at -78 οC under N2 
atmosphere. The reaction mixture was stirred overnight after warming up to RT slowly. The 
reaction was quenched with water in an ice-cooled bath, it was neutralized with aqueous 1 N 
NaHCO3 solution. The precipitate was collected by filtration and washed with water. The solid 
was dried in vacuo to afford 6 as a yellow solid (846 mg, 81%); mp 234 οC (dec.). 1H NMR 
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(DMSO-d6): δ 11.50 (s, 1H), 9.62 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.57 
(t, J = 7.5 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 7.28 (t, J = 8.0 Hz, 1H), 7.15 (s, 2H), 6.93 (d, J = 7.5 
Hz, 1H), 4.41 (s, 2H). 13C NMR (DMSO-d6): δ 164.7, 162.5, 157.5, 156.2, 135.1, 131.7, 130.1, 
124.4, 122.4, 121.9, 120.8, 120.1, 117.5, 112.8, 54.0. LC-MS (ESI, m/z): Calcd for C17H13N2O3 
([M+H]+) 293.1, found: 293.0. HRMS (ESI, m/z): Calcd for C18H15N2O3 ([M+H]+) 293.0926, 
found: 293.0916.  
 
3.7. tert-Butyl (3-(2-oxo-2,3-dihydro-1H-benzofuro[3,2-e][1,4]diazepin-5-yl)phenyl)carbonate 
(7)  
 
A suspension of compound 6 (50 mg, 0.17 mmol), (Boc)2O (250 mg, 1.14 mmol) and DMAP (9 
mg, 0.07 mmol) in CH3CN (2 mL) was stirred at RT for 2.5 h. The solvent was evaporated in 
vacuo. The crude product was purified by preparative TLC plate using CH2Cl2/MeOH (100:4) as 
eluent to afford 7 as a pale yellow solid (29 mg, 44%); mp 182-183 οC. 1H NMR (CDCl3): δ 11.2 
(s, 1H), 7.92 (d, J = 7.5 Hz, 1H), 7.69-7.67 (m, 2H), 7.53-7.52 (m, 2H), 7.45 (t, J = 8.0 Hz, 1H), 
7.42-7.38 (m, 1H), 7.33-7.30 (m, 1H), 4.63 (s, 2H), 1.55 (s, 9H). 13C NMR (DMSO-d6): δ 167.9, 
161.8, 154.2, 151.8, 151.2, 139.6, 137.6, 129.4, 128.8, 128.4, 126.8, 124.1, 123.8, 122.2, 121.0, 
120.2, 112.6, 83.9, 58.8, 27.8. HRMS (ESI, m/z): Calcd for C22H21N2O5 ([M+H]+) 393.1450, 
found: 393.1434. 
 
3.8. General procedure for preparation of compound 8 
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5-(3-Bromophenyl)-1-methyl-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (N-Me-5-
BDBD, 8c). To a stirred solution of compound 5c (200 mg, 0.56 mmol) in anhydrous DMF (2 
mL) was added NaH (60% dispersion in mineral oil, 16 mg, 0.67 mmol). The reaction mixture 
was stirred at RT for 15 min, and methyl iodide (70 µL, 1.12 mmol) was then added. After the 
mixture was stirred at RT for 30 min, it was poured into ice-water and extracted with EtOAc. 
The organic layer was washed with water, brine, dried over anhydrous Na2SO4 and filtered. The 
solvent was evaporated in vacuo. The crude product was purified by preparative TLC plate using 
CH2Cl2/MeOH (100:4) as eluent to afford 8c as a pale yellow solid (136 mg, 65%); mp 158-160 
οC. 1H NMR (DMSO-d6): δ 8.05 (d, J = 8.0 Hz, 1H), 7.94 (s, 1H), 7.80-7.75 (m, 3H), 7.60 (t, J = 
8.0 Hz, 1H), 7.47 (q, J = 8.0 Hz, 2H), 4.51 (br s, 2H), 3.57 (s, 3H). 13C NMR (CDCl3): δ 164.8, 
159.9, 153.4, 139.6, 137.7, 133.5, 131.9, 131.2, 130.6, 128.3, 128.0, 123.9, 121.8, 121.7, 121.5, 
112.8, 58.4, 33.9. HRMS (ESI, m/z): Calcd for C18H14BrN2O2 ([M+H]+) 369.0239, found: 
369.0254. 
5-(3-Methoxyphenyl)-1-methyl-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (8f). 
Compound 8f was prepared with similar procedure as compound 8c from 5f. Yield: 90%, pale 
yellow solid; mp 62-64 οC. 1H NMR (CDCl3): δ 7.81 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 8.5 Hz, 
1H), 7.53 (dt, J =1.5, 7.0 Hz, 1H), 7.43-7.35 (m, 4H), 7.08-7.05(m, 1H), 4.57 (br s, 2H), 3.86 (s, 
3H), 3.64 (s, 3H). 13C NMR (CDCl3): δ 166.1, 162.1, 159.8, 153.9, 141.1, 137.2, 131.5, 129.5, 
128.1, 123.9, 122.0, 121.9, 121.1, 117.4, 113.8, 113.1, 58.7, 55.6, 34.4. HRMS (ESI, m/z): Calcd 
for C19H17N2O3 ([M+H]+) 321.1239, found: 321.1234. 
 
3.9. 5-(3-Hydroxyphenyl)-1-methyl-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (N-Me-
5-BDBD analog, 9)  
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To a stirred solution of compound 8f (60 mg, 0.18 mmol) in anhydrous CH2Cl2 (1 mL) was 
added BBr3 (1.0 M solution in CH2Cl2, 1.4 mL, 1.4 mmol) dropwise at -78 οC under N2 
atmosphere. The reaction mixture was stirred overnight after warming up to RT slowly. The 
reaction was quenched with water in an ice-cooled bath, it was neutralized with aqueous 1 N 
NaHCO3 solution and extracted with CH2Cl2. The solvent was evaporated in vacuo. The crude 
product was purified by preparative TLC plate using CH2Cl2/MeOH (100:4) as eluent to afford 9 
as a pale yellow solid (41 mg, 72%); mp 227-228 οC. 1H NMR (DMSO-d6): δ 9.65 (s, 1H), 8.04 
(d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.61-7.58 (m, 1H), 7.46 (t, J = 7.5 Hz, 1H), 7.29 (t, 
J = 8.0 Hz, 1H), 7.20-7.19 (m, 2H), 6.95-6.93 (m, 1H), 4.46 (br s, 2H), 3.56 (s, 3H). 13C NMR 
(DMSO-d6): δ 165.3, 161.1, 157.3, 153.2, 140.4, 136.8, 131.3, 129.4, 128.1, 123.8, 121.7, 121.5, 
119.8, 117.9, 115.4, 112.7, 58.2, 33.8. LC-MS (ESI, m/z): Calcd for C18H15N2O3 ([M+H]+) 
307.1, found: 307.1. HRMS (ESI, m/z): Calcd for C18H15N2O3 ([M+H]+) 307.1083, found: 
307.1070. 
 
3.10. 2-(3-(2-Oxo-2,3-dihydro-1H-benzofuro[3,2-e][1,4]diazepin-5-yl)phenoxy)ethyl 4-
methylbenzenesulfonate (10) 
 
To a stirred solution of compound 6 (200 mg, 0.7 mmol) in anhydrous DMF (4 mL) was added 
NaH (60% dispersion in mineral oil, 82 mg, 2.0 mmol) at 0 οC under N2 atmosphere and the 
mixture was stirred at 0 οC for 45 min, followed by addition of 1,2-bis(tosyloxy)ethane (504 mg, 
1.4 mmol). After the reaction mixture was stirred at 0 οC for 6 h, it was poured into ice-water and 
extracted with EtOAc. The organic layer was washed with water, brine, dried over anhydrous 
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Na2SO4 and filtered. The solvent was evaporated in vacuo. The crude product was purified by 
preparative TLC plate using CH2Cl2/MeOH (100:4) as eluent to afford 10 as a yellow solid (144 
mg, 43%); mp 188-189 οC. 1H NMR (DMSO-d6): δ 11.55 (s, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.79 
(d, J = 8.5 Hz, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.60-7.56 (m, 1H), 7.44-7.36 (m, 4H), 7.30 (d, J = 
7.5 Hz, 1H), 7.13 (t, J = 2.0 Hz, 1H), 7.03-7.01(m, 1H), 4.44 (s, 2H), 4.37-4.35 (m, 2H), 4.21-
4.19 (m, 2H), 2.36 (s, 3H). 13C NMR (DMSO-d6): δ 165.9, 160.9, 157.6, 153.5, 144.9, 138.7, 
137.4, 132.3, 130.1, 129.5, 128.7, 128.5, 127.7, 123.5, 121.9, 120.8, 116.8, 114.6, 112.4, 69.1, 
65.4, 59.1, 21.0. LC-MS (ESI, m/z): Calcd for C26H23N2O6S ([M+H]+) 491.1, found: 491.1. 
HRMS (ESI, m/z): Calcd for C26H23N2O6S ([M+H]+) 491.1277, found: 491.1265. 
 
3.11. 5-(3-(2-Fluoroethoxy)phenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (FE-5-
BDBD, 11) 
 
To a stirred solution of compound 6 (100 mg, 0.3 mmol) in anhydrous DMF (2 mL) was added 
NaH (60% dispersion in mineral oil, 41 mg, 1.0 mmol) at 0 οC under N2 atmosphere and the 
mixture was stirred 0 οC for 45 min, followed by addition of a solution of 2-fluoroethyl tosylate 
(111 mg, 0.5 mmol) in anhydrous DMF (1 mL). After the reaction mixture was stirred at 0 οC for 
6 h, it was poured into ice-water and extracted with EtOAc. The organic layer was washed with 
water, brine, dried over anhydrous Na2SO4 and filtered. The solvent was evaporated in vacuo. 
The crude product was purified by preparative TLC plate using CH2Cl2/MeOH (100:4) as eluent 
to afford 11 as a yellow solid (75 mg, 65%); mp 215-216 οC. 1H NMR (DMSO-d6): δ 11.55 (s, 
1H), 8.00 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.59-7.56 (m, 1H), 7.44-7.41 (m, 2H), 
7.34-7.32 (m, 2H), 7.17-7.15 (m, 1H), 4.80 (t, J = 4.0 Hz, 1H), 4.71 (t, J = 4.0 Hz, 1H), 4.44 (s, 
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2H), 4.32 (t, J = 4.0 Hz, 1H), 4.26 (t, J = 4.0 Hz, 1H). 13C NMR (DMSO-d6): δ 165.9, 161.0, 
158.1, 153.5, 138.7, 137.4, 129.6, 128.7, 128.5, 123.5, 121.9, 120.8, 120.8, 117.1, 114.5, 112.4, 
82.7 (d, J = 165 Hz), 67.2, 59.1. LC-MS (ESI, m/z): Calcd for C19H16FN2O3 ([M+H]+) 339.1, 
found: 339.0. HRMS (ESI, m/z): Calcd for C19H16FN2O3 ([M+H]+) 339.1145, found: 339.1140. 
 
3.12. General procedure for preparation of carbon-11-labeled 5-BDBD analogs 
 
5-(3-Hydroxyphenyl)-1-[11C]methyl-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (N-
[11C]Me-5-BDBD analog, [11C]9) and 5-(3-bromophenyl)-1-[11C]methyl-1,3-dihydro-2H-
benzofuro[3,2-e][1,4]diazepin-2-one (N-[11C]Me-5-BDBD, [11C]8c). [11C]CO2 was produced by 
the 14N(p,α)11C nuclear reaction in the small volume (9.5 cm3) aluminum gas target provided 
with the Siemens RDS-111 Eclipse cyclotron. The target gas consisted of 1% oxygen in nitrogen 
purchased as a specialty gas from Praxair, Indianapolis, IN. Typical irradiations used for the 
development were 58 µA beam current and 15 min on target. The production run produced 
approximately 25.9 GBq of [11C]CO2 at EOB. The precursor (6 or 5c, 0.1-0.3 mg) was dissolved 
in CH3CN (300 µL). To this solution was added NaH (95% dispersion in mineral oil, 1 mg). The 
mixture was transferred to a small reaction vial. No-carrier-added (high specific activity) 
[11C]CH3OTf that was produced by the gas-phase production method20 within 12 min from 
[11C]CO2 through [11C]CH4 and [11C]CH3Br with silver triflate (AgOTf) column was passed into 
the reaction vial at RT until radioactivity reached a maximum (2 min), and then the reaction vial 
was isolated and heated at 80 °C for 3 min. The contents of the reaction vial were diluted with 
aqueous NaHCO3 (0.1 M, 1 mL). The reaction vial was connected to a 3-mL HPLC injection 
loop. The labeled product mixture solution was injected onto the semi-preparative HPLC column 
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for purification. The product fraction was collected in a recovery vial containing 30 mL water. 
The diluted tracer solution was then passed through a C-18 Sep-Pak Light cartridge, and washed 
with water (3 × 10 mL). The cartridge was eluted with EtOH (3 × 0.4 mL) to release the labeled 
product, followed by saline (10-11 mL). The eluted product was then sterile-filtered through a 
Millex-FG 0.2 µm membrane into a sterile vial. Total radioactivity of [11C]9 or [11C]8c was 
assayed and total volume (10-11 mL) was noted for tracer dose dispensing. The overall synthesis 
time including HPLC-SPE purification and reformulation was ~40 min from EOB. The decay 
corrected radiochemical yield for [11C]9 and [11C]8c was 30-50%. Retention times in the 
analytical HPLC system performed using a Prodigy (Phenomenex) 5 µm C-18 column, 4.6 × 250 
mm; mobile phase 30% CH3CN/70% 20 mM H3PO4; flow rate 1.0 mL/min; and UV (254 nm) 
and γ-ray (PIN diode) flow detectors were: tR 6 = 3.68 min, tR 9 = 6.61 min, tR [11C]9 = 6.66 min. 
Retention times in the semi-preparative HPLC system performed using a Prodigy (Phenomenex) 
5 µm C-18 column, 10 × 250 mm; mobile phase 30% CH3CN/70% 20 mM H3PO4; flow rate 5.0 
mL/min; and UV (254 nm) and γ-ray (PIN diode) flow detectors were: tR 6 = 4.88 min, tR 9 = 
7.65 min, tR [11C]9 = 7.77 min. Retention times in the analytical HPLC system performed using a 
Prodigy (Phenomenex) 5 µm C-18 column, 4.6 × 250 mm; mobile phase 70% CH3CN/30% H2O; 
flow rate 1.3 mL/min; and UV (254 nm) and γ-ray (PIN diode) flow detectors were: tR 5c = 4.11 
min, tR 8c = 6.12 min, tR [11C]8c = 6.19 min. Retention times in the semi-preparative HPLC 
system performed using a Prodigy (Phenomenex) 5 µm C-18 column, 10 × 250 mm; mobile 
phase 70% CH3CN/30% H2O; flow rate 5.0 mL/min; and UV (254 nm) and γ-ray (PIN diode) 
flow detectors were: tR 5c = 3.56 min, tR 8c = 7.91 min, tR [11C]8c = 8.00 min. 
 
3.13. General procedure for preparation of fluorine-18-labeled 5-BDBD analogs 
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5-(3-[18F]Fluorophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one ([18F]F-5-BDBD, 
[18F]5a) and 5-(3-(2-[18F]fluoroethoxy)phenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-
2-one ([18F]FE-5-BDBD, [18F]11). No-carrier-added (NCA) aqueous H[18F]F was produced by 
18O(p,n)18F nuclear reaction using a Siemens Eclipse RDS-111 cyclotron by irradiation of H218O 
(2.5 mL). [18F]Fluoride (7.4-18.5 GBq) in [18O]water plus 0.1 mL K2CO3 solution (1.7 mg) and 
Kryptofix 2.2.2 (10 mg) in 1.0 mL CH3CN were placed in the fluorination reaction vial (5-mL 
V-vial) and repeated azeotropic distillation was performed at 110 °C to remove water and to 
form the anhydrous K[18F]F-Kryptofix 2.2.2 complex.  Nitro- precursor 5e or tosylated precursor 
10 (1 mg) dissolved in DMSO (1.0 mL) was introduced to the reaction vessel and heated at 140 
°C for 20 min to affect radiofluorination. After cooling to ~90 °C, aqueous NaHCO3 (0.1 M, 1 
mL) was added to the reaction vessel for dilution, at which time the reaction mixture was loaded 
into a 3-mL injection loop for introduction to the semi-preparative reverse-phase (C18) HPLC 
column for initial purification of the labeled product. The HPLC fraction containing [18F]5a or 
[18F]11 eluted from the column was automatically collected in a recovery vial containing 30 mL 
water. The diluted tracer solution was then passed through a C-18 Sep-Pak Plus cartridge, and 
washed with water (5 × 5 mL). The cartridge was eluted with EtOH (2 × 1 mL) to release [18F]5a 
or [18F]11. The eluted product was then sterile-filtered through a Millex-FG 0.2 µm membrane 
into a sterile vial and formulated with 10 mL saline. Total radioactivity was assayed and total 
volume was noted for tracer dose dispensing. The overall decay-corrected radiochemical yield 
from K[18F]F for [18F]5a and [18F]11 was 5-15% and 15-25%, respectively. Retention times in 
the semi-preparative HPLC system performed using a YMC-Pack ODS-A (Phenomenex), S-5 
µm, 12 nm, 10×250 mm C-18 column; 30% CH3CN/70% 20 mM H3PO4 (pH 2.5) mobile phase; 
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5.0 mL/min flow rate; UV (254 nm) and γ-ray (PIN diode) flow detectors were: tR 5e = 9.65 min, 
tR 5a = 12.64 min, tR [18F]5a = 12.71 min; tR 10 = 19.13 min, tR 11 = 8.87 min, tR [18F]11 = 8.95 
min. Retention times in the analytical HPLC system performed using a Prodigy (Phenomenex) 5 
µm C-18 column, 4.6 × 250 mm; mobile phase 30% CH3CN/70% 20 mM H3PO4; flow rate 1.3 
mL/min; and UV (254 nm) and γ-ray (PIN diode) flow detectors were: tR 5e = 6.59 min, tR 5a = 
9.94 min, tR [18F]5a = 10.02 min; tR 10 = 10.55 min, tR 11 = 6.89 min, tR [18F]11 = 7.03 min. 
  
3.14. In vitro binding studies 
 
Cell culture and membrane preparation. HEK293 cells expressing human recombinant P2X4 
receptors were obtained from B’SYS GmbH and cultured according to supplier’s procedure. 
Cells were grown to 80% confluency then rinsed with phosphate buffered saline (PBS), detached 
with trypsin and harvested. Cell pellets were obtained by centrifugation at 200xG for 5 min at 4 
°C.  Collected cell pellets were frozen at -80 °C until membrane preparation. For the membrane 
preparation, pellets from ten T225 flasks were homogenized in 50 mM Tris-HCl, 1 mM EDTA 
pH 7.4 plus 0.1% bacitracin, 100 µM PMSF at 4 °C. The homogenate was then centrifuged at 
48000×G for 20 min at 4 °C, gently rinsed with de-ionized water then resuspended in 5 mL of 
buffer pH 7.4 at 4 °C.  This homogenate was then frozen at -80 °C, then thawed, an additional 30 
mL buffer added and centrifuged as before. The freeze/thaw procedure repeated once. The final 
resulting pellet was homogenized in buffer, total protein concentration determined via Bradford 
protein assay (Bio-Rad), aliquoted into cryovials and stored at -80 °C until day of assay.   
Radioligand depletion experiments. Radioligand depletion experiments were performed to 
measure the bound radioligand concentration. Four replicates of membrane preparation (0.004-
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4.5 mg protein/mL assay medium) were incubated with 10 nM or 100 nM [11C]9 or [11C]8c in a 
final volume of 0.2 mL in assay buffer (50 mM Tris-HCl, 1 mM EDTA pH 7.4 plus 0.1% 
bacitracin, 100 µM PMSF) for 30 min at 37 °C. Unlabeled compound 9 or 8c was added at 100 
fold excess of [11C]9 or [11C]8c to determine non-specific binding. To measure the total 
radioactivity added to the experiment, 20 µL of stock radioligand (amount added to each 
experimental well) was spotted onto a unifilter GF/B plate then allowed to air dry. An additional 
aliquot was added to scintillation vial and counted on a Beckman LSC to determine CPMs 
(counts per minute) added. For termination of the binding reaction, the samples were filtered 
onto GF/B unifilter plates that had been pre-soaked in 20 mM tetrasodium pyrophosphate for 30 
min using a unifilter-96 cell harvester (Perkin-Elmer). Plates were washed 6 times with ice cold 
saline, dried under a vacuum, and exposed to a TR2025 phosphorscreen (GE Healthcare) for 20 
to 60 min. Phosphorscreens were then read on Typhoon FLA-7000IP (GE Healthcare) along with 
[11C]9 or [11C]8c calibration standards. CPMs were determined by calibrating the image to the 
CPMs in the calibration standards via MCID analysis Software. 
Ligand competitive binding assays. Cell membrane preparation (5 µg per well) was incubated 
with 11 compound concentrations over a six log unit range, with 0.2 nM [35S]ATPγS (Perkin 
Elmer) in assay buffer. Triplicate determinations were done at each concentration of test 
compound 5-BDBD (5c), N-Me-5-BDBD (8c), N-Me-5-BDBD analog (9), F-5-BDBD (5a) or 
FE-5-BDBD (11). Unlabeled ATP was used to determine non-specific binding. Each assay plate 
included a positive control (ATP) and a negative control (buffer). Assays were incubated at 4 °C 
for 2 h. After equilibrium was reached, bound radioligand was separated from free radioligand 
using a Perkin Elmer 96-well filtration apparatus. Plates were washed at least 3 times with ice 
cold saline. Filters were quickly dried under a vacuum and radioactive counts collected on a 
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Perkin Elmer TopCount microplate scintillation counter using a protocol for 35S. Data was 
analyzed with Prism 7 (GraphPad Software Inc.) to determine Ki values. 
 
 
4. Conclusions 
 
In summary, improved and efficient syntheses of a series of new 5-BDBD analog precursors (for 
C-11 and F-18 labeling) and reference standards with moderate to high chemical yields have 
been developed. The amide precursors were labeled with [11C]CH3OTf via N-[11C]methylation, 
and isolated by a semi-preparative HPLC purification combined with SPE procedure to provide 
carbon-11-labeled 5-BDBD analogs in high radiochemical yields, short overall synthesis time, 
and good specific radioactivity. The nitro- and tosylated precursors were labeled with 
K[18F]F/Kryptofix 2.2.2 through nucleophilic substitution and isolated by a semi-preparative 
HPLC combined with SPE method to produce fluorine-18-labeled 5-BDBD analogs in 
reasonable radiochemical yield and good specific radioactivity. The preliminary biological 
evaluation of radiolabeled 5-BDBD analogs indicated they have similar biological activity with 
the parent compound 5-BDBD. It is anticipated that the approaches described here can be 
applied with advantage to the development of more potent PET P2X4 radioligands, and other 
receptor- and/or enzyme-based 11C- and 18F-radioligands for PET imaging. 
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